VIA
PCRX icon

Vident Investment Advisory’s Pacira BioSciences PCRX Stock Holding History

Vident Investment Advisory’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-11,985
Closed -$1.06M – 1071
2015
Q1 		$1.06M Buy
+11,985
New +$1.22M 0.21% 124

Other funds holding PCRX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCM
Marsico Capital Management Denver, Colorado $3.4B AUM 51.58% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Vident Investment Advisory's PCRX Position: Q2 2015 in Review

Vident Investment Advisory sold out of Pacira BioSciences (PCRX) in Q2 2015, closing a stake of 11,985 shares — an estimated $1.06M sold.

Vident Investment Advisory first reported a position in PCRX in Q1 2015 and held it in 1 quarter. The position peaked at $1.06M in Q1 2015. 187 funds tracked by Wall St. Rank hold PCRX as of Q2 2015.

  • Vident Investment Advisory reported no remaining Pacira BioSciences position as of Q2 2015 after selling out during the quarter.
  • Vident Investment Advisory sold 11,985 Pacira BioSciences shares in Q2 2015, an estimated $1.06M.
  • Vident Investment Advisory first reported a position in Pacira BioSciences in Q1 2015 and held it in 1 quarter.
  • Vident Investment Advisory's Pacira BioSciences position peaked at $1.06M in Q1 2015.
  • 187 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2015.

Based on Vident Investment Advisory's 13F filing for Q2 2015, filed 29 Jul 2015.